Management of Steroid-Resistant Idiopathic Urticaria
For idiopathic (chronic spontaneous) urticaria that remains uncontrolled despite systemic steroids, you should immediately discontinue prolonged steroid use and escalate to omalizumab as the preferred second-line therapy, with cyclosporine reserved as a third-line alternative for severe refractory cases. 1
Critical First Step: Stop Prolonged Steroids
The 2026 international guideline strongly recommends against long-term use of systemic corticosteroids in chronic urticaria 1. While short courses (maximum 10 days) may help acute exacerbations, prolonged use at the doses needed to control urticaria (20-50 mg/day prednisone equivalent) causes unacceptable long-term side effects 1. If a patient is "resistant" to steroids, this signals the need for escalation, not continued steroid therapy.
The Treatment Algorithm
First-Line: Optimize Antihistamines First
Before labeling urticaria as truly refractory, ensure the patient has received:
- Second-generation H1-antihistamines up-dosed to 4-fold the standard dose 1, 2
- Examples: cetirizine 40 mg daily, desloratadine 20 mg daily, fexofenadine 720 mg daily
- Trial for 2-4 weeks at maximum dose before declaring failure 2
Second-Line: Omalizumab (Preferred)
Omalizumab is the cornerstone biologic therapy for antihistamine-refractory chronic spontaneous urticaria 2, 3:
- Dosing: 150-300 mg subcutaneously every 4 weeks (approved dose) 2
- Efficacy: Achieves complete disease control in approximately 70% of antihistamine-refractory cases 3
- Safety profile: Excellent, with no major adverse events 2
- Response time: Can be rapid, often within first few doses
For partial responders: Consider dose escalation to 600 mg every 2 weeks or shortening intervals 2
Predictors of poor omalizumab response (suggesting type IIb autoimmune CSU):
- Low total IgE levels
- Basopenia
- Positive basophil activation test
- Other autoimmune markers 4
Third-Line: Cyclosporine A
For patients who fail omalizumab or have contraindications 1, 2:
- Dosing: Start at 3-5 mg/kg/day divided twice daily 2
- Particularly effective in: Type IIb autoimmune CSU (those with low IgE, autoantibodies) 5, 4
- Monitoring required: Kidney function, blood pressure, cyclosporine levels 2, 5
- Duration: Can be used long-term at very low doses (1-2 mg/kg/day) with appropriate monitoring 5
Common pitfall: Starting cyclosporine at too high a dose. Begin at 1 mg/kg/day and titrate based on response to minimize adverse effects while preserving efficacy 5.
Fourth-Line: Emerging Options
For true omalizumab-refractory cases 3, 4:
- Dupilumab: Recently approved add-on therapy
- Remibrutinib (BTK inhibitor): Recently approved
- These provide additional options particularly for type IIb autoimmune CSU
Alternative Agents with Lower Evidence
When guideline-recommended treatments are unavailable or contraindicated, consider 1:
- Sulfasalazine: 74% reported significant improvement in one case series; steroid-sparing effect 6
- Dapsone, methotrexate, hydroxychloroquine: Low-quality evidence but may be affordable alternatives in resource-limited settings 1, 7
- Leukotriene receptor antagonists (montelukast): Can be added to antihistamines 2
What NOT to Do
- Never continue long-term systemic corticosteroids - this is explicitly contraindicated 1
- Don't delay escalation - prolonged ineffective antihistamine therapy without advancing treatment prevents disease control 2
- Avoid depot steroid preparations - strongly recommended against 1
- Don't use topical corticosteroids - not useful in urticaria (except possibly pressure urticaria on soles) 1
Monitoring and Re-evaluation
- Assess disease activity using validated tools: Urticaria Activity Score (UAS7) and Urticaria Control Test (UCT) 2, 4
- Re-evaluate treatment necessity every 3-6 months - spontaneous remission can occur 1
- Target: UCT score ≥12 indicates adequate control 2
Special Considerations
Trigger avoidance may help but has limited evidence: